Galectin Therapeutics reported $9.54M in Current Liabilities for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Bristol Myers Squibb BMY:US $ 20915M 1906M
Galectin Therapeutics GALT:US $ 9.54M 0.5M
Gilead Sciences GILD:US $ 9220M 662M
Idera Pharmaceuticals IDRA:US $ 4.74M 0.94M
Intercept Pharmaceuticals ICPT:US $ 151.43M 0.39M
Regulus Therapeutics RGLS:US $ 4.7M 0.53M
Vital Therapies VTL:US $ 10.4M 1.06M
YTE INCY:US $ 926.67M 40.51M